GL1X · GenesisL1 explorer

Research workbench

Crystal structure of SARS COV2 main protease in complex with inhibitor boceprevir

Analyse Crystal structure of SARS COV2 main protease in complex with inhibitor… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
6ZRU
Type
protein
Length
304 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Main protease
EC
3.4.19.12, 3.4.22.-, 3.4.22.69, 2.7.7.48, 3.6.4.12, 3.6.4.13, 3.1.13.-, 3.1.-.-, 2.1.1.-
UniProt
P0DTD1
Ligands
U5G
Pockets
2 · best druggability 0.55

Structure

x-ray diffraction · 1 distinct chain · 26% helix, 29% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMain protease (EC 3.4.19.12, 3.4.22.-, 3.4.22.69, 2.7.7.48, 3.6.4.12, 3.6.4.13, 3.1.13.-, 3.1.-.-, 2.1.1.-)protein30426% helix, 29% strandP0DTD1

Ligands and binding sites

  • U5G · boceprevir (bound form) · ligand · chains A
  • DMS · Dimethyl sulfoxide · additive · 2 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

2 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
12380.550.7841DMS
21630.490.7721U5G

Modifications

Observed in the structure: 1 covalent (covalent ligand).

Compared structures

  • 6ZRU · Crystal structure of SARS CoV2 main protease in complex with inhibitor Boceprevir · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.